Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's ...

Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head clinical trial.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

美股三大指数集体高开，纳指涨0.58%，标普500指数涨0.31%，道指涨0.49%。美国11月“小非农”ADP就业人数增加14.6万人，而市场预期为15万人，10月数据由23.3万人修正至18.4万人。赛富时涨超10%，第三财季业绩超预期，当前剩余 ...

美股开盘：三大指数集体高开。美股三大指数集体高开，道指涨0.44%，纳指涨0.57%，标普500指数涨0.31%。芯片公司Marvell涨近16%，AI需求强劲，公司销售额环比增19%，大超预期。礼来涨近2%，礼来减肥药Zepbound在首次对比试验中超越诺和诺德的Wegovy。

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...